RxDoctor Payments Data

Jessica Saunders

Family · Roanoke, VANPI 1881148732

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,720 of the $11,825 with a category attached, or 82.2%. Mallinckrodt Hospital Products Inc. accounts for 96.7% of it on its own, with 5 other manufacturers making up the rest. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,825in general payments, 2019–2025

Across 32 payments — averaging $369.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$11K
  • Vifor Pharma, Inc.$238
  • Akebia Therapeutics Inc$67
  • Abbott$55
  • Bayer$21
  • AstraZeneca$11

What the payments were for

  • Speaking & faculty fees$9,72082%
  • Travel & lodging$1,42212%
  • Food & beverage$6596%
  • Education$240%

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,825 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$105,694
Medicare patients
247
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$38,175
JanuviaSitagliptin Phosphate37$13,756
FarxigaDapagliflozin Propanediol18$10,436
XareltoRivaroxaban14$8,046
Gabapentin350$7,814
JardianceEmpagliflozin11$6,718
Lacosamide21$5,961
LantusInsulin Glargine,hum.Rec.Anlog23$2,947
Oxycodone Hcl112$2,841
Lantus SolostarInsulin Glargine,hum.Rec.Anlog75$2,784
Memantine Hcl36$2,248
Divalproex Sodium61$2,160
Mirtazapine69$2,105
Tramadol Hcl102$1,716
Nystatin62$1,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$11$10,43618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →